Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecology and Fertility

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Regression rate at 6 months · women with atypical endometrial hyperplasia

It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 2.76 [0.26, 29.73]
1 study · 19 participants
Very low

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Nausea · women with atypical endometrial hyperplasia

It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 0.58 [0.28, 1.18]
1 study · 153 participants
Very low

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia

Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 2.89 [1.11, 7.52]
1 study · 153 participants
Low